These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21332245)

  • 1. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.
    Tobaiqy M; Stewart D; Helms PJ; Williams J; Crum J; Steer C; McLay J
    Drug Saf; 2011 Mar; 34(3):211-9. PubMed ID: 21332245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study to evaluate a community pharmacy-based monitoring system to identify adverse drug reactions associated with paediatric medicines use.
    Tobaiqy M; Stewart D; Helms PJ; Bond C; Lee AJ; Bateman N; McCaig D; McLay J
    Eur J Clin Pharmacol; 2010 Jun; 66(6):627-32. PubMed ID: 20195588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring adverse drug reactions in children using community pharmacies: a pilot study.
    Stewart D; Helms P; McCaig D; Bond C; McLay J
    Br J Clin Pharmacol; 2005 Jun; 59(6):677-83. PubMed ID: 15948932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate and stuttering.
    Trenque T; Claustre G; Herlem E; Djerada Z; Trenque A; Morel A; Azzouz B
    Br J Clin Pharmacol; 2019 Nov; 85(11):2634-2637. PubMed ID: 31418914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany.
    Knopf H; Du Y
    Br J Clin Pharmacol; 2010 Sep; 70(3):409-17. PubMed ID: 20716242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.
    Efron D; Jarman FC; Barker MJ
    J Paediatr Child Health; 1998 Jun; 34(3):288-92. PubMed ID: 9633980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inventory of European data sources for the long-term safety evaluation of methylphenidate.
    Murray ML; Insuk S; Banaschewski T; Neubert AC; McCarthy S; Buitelaar JK; Coghill D; Dittmann RW; Konrad K; Panei P; Rosenthal E; Sonuga-Barke EJ; Wong IC
    Eur Child Adolesc Psychiatry; 2013 Oct; 22(10):605-18. PubMed ID: 23508655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Health Product-Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication.
    Mazhar H; Foster BC; Necyk C; Gardiner PM; Harris CS; Robaey P
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):38-47. PubMed ID: 31670573
    [No Abstract]   [Full Text] [Related]  

  • 15. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies.
    Aagaard L; Hansen EH
    Neuropsychiatr Dis Treat; 2011; 7():729-44. PubMed ID: 22247615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of methylphenidate and reporting of valvular heart disease: Global pharmacovigilance analysis in children and adults.
    Ayme-Dietrich E; Kaguelidou F; Bertschy G; Chouchana L
    Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5814. PubMed ID: 38837561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.